A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.
about
Current and emerging azole antifungal agentsOutcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazoleVirulence-Associated Enzymes of Cryptococcus neoformansIn vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformansIn vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformansTreatment of cryptococcosis in the setting of HIV coinfection.Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.History of medical mycology in the united states.A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection.The gene encoding phosphoribosylaminoimidazole carboxylase (ADE2) is essential for growth of Cryptococcus neoformans in cerebrospinal fluid.Cryptococcal meningitis: epidemiology and therapeutic options.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerDetection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologiesThe cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.Metabolism-based drug interactions involving oral azole antifungals in humans.Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxisClinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theExpanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis.Central nervous system infection during immunosuppression.AIDS related opportunistic infections, going but not gone.Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice.Fluconazole penetration in cerebral parenchyma in humans at steady stateAntifungal therapy: from amphotericin B to present.Antifungal prophylaxis during neutropenia and immunodeficiencyAntimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal.2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.Costs of pharmaceutical care: can the profession do anything?Rapid and sensitive assay for fluconazole which uses gas chromatography with electron capture detectionOpportunistic infections in HIV-infected patients.Prevention of HIV-associated opportunistic infections and diseases in the age of highly active antiretroviral therapy.Cryptococcal Meningitis: Diagnosis and Management Update.Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans.Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models.Two-site comparison of broth microdilution and semisolid agar dilution methods for susceptibility testing of Cryptococcus neoformans in three media.Comparison of commercial kits for detection of cryptococcal antigenEmerging disease issues and fungal pathogens associated with HIV infectionCurrent options in antifungal pharmacotherapy.New Insights into HIV/AIDS-Associated Cryptococcosis.A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins.
P2860
Q24550733-2255AB44-D80B-419F-ADEC-AEB667987DE6Q24678763-577D2D88-20A6-47FD-B00C-A9F1B493DFB8Q26785005-361DA1A0-A7CE-4AAA-B7BC-12B0CABD1FB0Q28369024-0B223BD5-D53A-412E-8718-F1661B67F2A6Q28379195-D0E34EC5-4212-4D3B-A0D2-644233A5B9D7Q30366117-CE36D1E1-1AF6-49ED-8ECD-D037A6FEB2A4Q30424017-328B8FD3-70F4-42E8-9965-1C0C8BDB9F56Q30452877-5F752570-CC70-4CB5-9FB2-8A6A0D5D0BAEQ30844823-8775CA9D-30D1-42E3-9347-FBCDFBF60A8EQ33612121-5A2B0D82-12A3-4A13-B7CA-E524656805EAQ33633343-80514112-7E8F-4C62-ADCA-9D2506AA2B02Q33650105-0D88FD5E-E251-417E-89CF-602ED31BE16DQ33677651-62985815-908D-47ED-83D3-BDDAADDB0F91Q33710740-AD8F961C-472A-4B80-AC59-08D1B3E7B076Q33719828-F16E8327-748F-4A35-895D-C13AF6CF4664Q33892987-B89E1F54-A497-4056-BAEE-23A88A6D74B2Q34020746-227ACC1B-2134-4E1B-97E8-16853510496CQ34212799-537E09DF-9F78-4164-BB4A-E2F18A2A8F94Q34393599-171BA25C-550E-4EFD-ACB6-9A775CB6CBFDQ34469041-F8E5D3DD-5DF8-45CC-A678-B26C4F0F15B0Q34756259-95A7A068-0829-43C7-BB61-439BE0BB285BQ35066122-1C11FCFD-7701-4186-AAA4-DAEE21122D8DQ35114601-DD3C83AD-3E84-4AA9-BB59-51B3788213D5Q35245371-A3A86D91-C3A7-42F1-B63D-2AC05C22CA2FQ35374928-23BCCCF8-FD0D-49C2-869B-82F3762271C4Q35557331-157C77E6-19B1-449F-A028-9D6FAC47AD92Q35614631-802009E0-9CAD-46E5-ACD1-48A5820C0BE6Q35657210-43E60DDE-6F42-4A87-B887-25FDB3E2E04DQ35867277-AA5F2432-497B-4810-837F-72130AB6D6EDQ35893214-74A701F3-40F4-48A7-BA00-829853272D19Q35917465-7308956D-CC82-474E-B6FD-30F57197F3A5Q35951094-02F12204-5EB0-47A3-BD35-4D774AF0E986Q35953363-A5BFFA07-4BF9-49A0-967E-5EB9C19856FEQ36192774-13E19417-14DE-42FD-BEED-41D124DDF61FQ37068914-207F39FE-5206-49B4-A91D-B68D753B2ECDQ37087955-F6A61783-D5C8-4423-8C8B-82198A35EC5FQ37091704-8B3A8818-754B-4264-B643-DC5D2774FBD8Q37151326-F0EA2D4A-6BDF-4E59-953F-0FFFCF971296Q37156556-DB40A716-631D-45A6-BEF8-D29C9DC8D737Q37367575-0ADD9304-0E10-456C-8C69-FCECE7E23A66
P2860
A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
A placebo-controlled trial of ...... Collaborative Treatment Group.
@en
A placebo-controlled trial of ...... Collaborative Treatment Group.
@nl
type
label
A placebo-controlled trial of ...... Collaborative Treatment Group.
@en
A placebo-controlled trial of ...... Collaborative Treatment Group.
@nl
prefLabel
A placebo-controlled trial of ...... Collaborative Treatment Group.
@en
A placebo-controlled trial of ...... Collaborative Treatment Group.
@nl
P2093
P921
P1476
A placebo-controlled trial of ...... Collaborative Treatment Group.
@en
P2093
Bozzette SA
Jacobsen J
McCutchan JA
Robinson P
P304
P356
10.1056/NEJM199102283240902
P407
P577
1991-02-01T00:00:00Z